Cytovale’s rapid diagnostic slashes sepsis mortality by 39%, peer-reviewed study confirms
June 13, 2025
One of the largest real-world studies of a sepsis diagnostic reveals that Cytovale’s IntelliSep, a U.S. Food and Drug Administration (FDA)-cleared rapid host response diagnostic, reduced the relative rate of sepsis mortality by 39%, shortened length of hospital stay, and enabled more efficient resource allocation in the emergency department (ED).
The study, “Impact of a Sepsis Quality Improvement Initiative on Clinical and Operational Outcomes,” published in the peer-reviewed journal Healthcare, followed more than 12,000 patients over 12 months at Our Lady of the Lake Regional Medical Center (OLOLRMC), a 900-bed in-patient acute care facility and Level 1 trauma center in Baton Rouge, La.
Key study findings:
- 39% relative rate reduction in sepsis mortality, with non-sepsis mortality unchanged, validating the impact of IntelliSep on targeted triage.
- 0.76 day decrease in average hospital length of stay for sepsis patients, with strong implications for improved throughput and cost reduction.
- 40% decrease in blood culture usage in low risk patients and an 8% increase in high-risk cases.
